Zai Lab revenue falls 10% as ZEJULA, VYVGART face pricing and generic headwinds

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Product revenue declined 10% YoY to $95.6M, reversing prior-year 21% growth. ZEJULA sales fell 39% ($49.5M to $30.0M) due to generic olaparib volume-based procurement shifting hospital utilization; VYVGART dropped 3% ($18.1M to $17.6M) from NRDL renewal pricing cuts.

  MD&A: Revenue verify on EDGAR →
• high

  Partner Vertex reported positive Phase 3 interim data for povetacicept in IgAN (52% reduction in proteinuria vs. placebo, p<0.0001). Zai participated in the Greater China portion of the global RAINIER trial, positioning the asset for potential China filing.

  MD&A: Povetacicept verify on EDGAR →
• high

  Zoci (DLL3-targeting ADC) showed 53.7% intracranial response rate in ES-SCLC with brain metastases (62.5% at 1.6 mg/kg dose) and 38.2% response in extrapulmonary NECs. Company announced clinical collaborations with Amgen and Boehringer Ingelheim to evaluate combinations with bispecific T-cell engagers.

  MD&A: Zoci Clinical Data verify on EDGAR →